Precigen, Inc. (PGEN)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Precigen, Inc. (PGEN) trades at $5.64 with AI Score 14/100 (Grade F). Precigen, Inc. is a biotechnology company focused on developing gene and cell therapies. Market cap: $1.69B, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for PGEN: PGEN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PGEN against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PGEN: 1/1 perspectives are bearish.
How is this calculated? →Precigen, Inc. (PGEN) Healthcare & Pipeline Overview
Precigen, Inc. is a biotechnology firm specializing in gene and cell therapy development, leveraging platforms like UltraVector and AdenoVerse to create innovative therapeutics and biotechnology solutions. With a focus on disease modification and regenerative medicine, Precigen operates in a competitive landscape of advanced biotechnology companies.
What Is the Investment Thesis for PGEN?
Precigen, Inc. presents a high-risk, high-reward investment thesis centered on its innovative gene and cell therapy platforms. Key value drivers include the successful development and commercialization of its UltraCAR-T and AdenoVerse Immunotherapy platforms. The company's diverse technology portfolio offers multiple avenues for growth, but its negative profit margin of -2588.2% highlights the significant financial challenges. Upcoming catalysts include clinical trial results for its lead candidates and potential partnerships. Investors should monitor the company's cash burn rate and ability to secure additional funding. The company's beta of 1.12 suggests higher volatility compared to the overall market.
Based on FMP financials and quantitative analysis
PGEN Key Highlights
- Market capitalization of $1.69B reflects investor expectations for future growth in the gene and cell therapy market.
- Gross margin of 42.1% indicates potential for profitability as products move through clinical trials and towards commercialization.
- The company's focus on innovative platforms like UltraVector and AdenoVerse positions it at the forefront of gene and cell therapy development.
- Collaboration agreements with multiple companies demonstrate the potential for partnerships and revenue generation.
- Change of name from Intrexon Corporation to Precigen, Inc. in January 2020 signifies a strategic shift towards a more focused approach on gene and cell therapies.
Who Are PGEN's Competitors?
PGEN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| TERN Terns Pharmaceuticals, Inc. | $52.95 | -0.03% | $4.77B | 51 |
| DNTH Dianthus Therapeutics, Inc. | $91.31 | -3.21% | $3.81B | — |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PGEN's Key Strengths?
- Innovative technology platforms (UltraVector, AdenoVerse).
- Diverse portfolio of therapeutic programs.
- Strategic collaborations with leading companies.
- Expertise in gene and cell therapy development.
What Are PGEN's Weaknesses?
- High operating expenses and negative profit margin.
- Dependence on clinical trial outcomes.
- Limited commercialized products.
- Potential regulatory hurdles.
What Could Drive PGEN Stock Higher?
- Clinical trial results for UltraCAR-T platform in hematological malignancies.
- Data readout from AdenoVerse immunotherapy studies in solid tumors.
- Potential partnerships for commercialization of ActoBiotics platform.
- Advancements in regenerative medicine applications using genetically engineered swine.
- Expansion of intellectual property portfolio through new patent filings.
What Are the Key Risks for PGEN?
- Financial-distress signal — its Altman Z-Score of -18.95 sits in the distress zone (elevated bankruptcy risk).
- Unfavorable clinical trial results for key therapeutic programs.
- Regulatory delays or rejections for new products.
- Competition from established pharmaceutical companies.
- High operating expenses and cash burn rate.
- Patent disputes and intellectual property challenges.
What Are the Growth Opportunities for PGEN?
- UltraCAR-T Platform Expansion: Precigen's UltraCAR-T platform represents a significant growth opportunity in the oncology market. The global CAR-T cell therapy market is projected to reach $5.29 billion by 2029, growing at a CAGR of 21.7% from 2022. By expanding the application of its UltraCAR-T platform to treat a broader range of cancers, Precigen can capture a larger share of this expanding market. This involves ongoing clinical trials and potential partnerships with other pharmaceutical companies to accelerate development and commercialization.
- AdenoVerse Immunotherapy Development: The AdenoVerse Immunotherapy platform offers a growth avenue through the development of novel immunotherapies. The global immunotherapy market is expected to reach $414.4 billion by 2030, growing at a CAGR of 13.3% from 2021. Precigen can leverage its AdenoVerse platform to create targeted immunotherapies for various diseases, including cancer and infectious diseases. Success hinges on positive clinical trial results and strategic collaborations to expand the platform's reach.
- Regenerative Medicine Applications: Precigen's genetically engineered swine for regenerative medicine applications presents a unique growth opportunity. The regenerative medicine market is projected to reach $121.6 billion by 2030, growing at a CAGR of 21.8% from 2021. By developing and commercializing genetically engineered tissues and organs for transplantation, Precigen can address the critical shortage of donor organs and improve patient outcomes. This requires overcoming regulatory hurdles and establishing partnerships with transplant centers.
- ActoBiotics Platform Commercialization: The ActoBiotics platform, which delivers proteins and peptides at mucosal sites, offers a growth opportunity in the treatment of gastrointestinal and other mucosal diseases. The global market for microbiome therapeutics is expected to reach $1.79 billion by 2028, growing at a CAGR of 22.1% from 2021. Precigen can leverage its ActoBiotics platform to develop targeted therapies for conditions like inflammatory bowel disease and infectious diarrhea. This involves conducting clinical trials and securing regulatory approvals for its ActoBiotics-based products.
- Strategic Partnerships and Licensing Agreements: Precigen can drive growth through strategic partnerships and licensing agreements with other biotechnology and pharmaceutical companies. By collaborating with partners to develop and commercialize its technologies, Precigen can expand its reach and access new markets. This includes licensing its UltraVector, AdenoVerse, and ActoBiotics platforms to other companies for use in their own research and development programs. Successful partnerships can provide significant revenue streams and accelerate the development of Precigen's technologies.
What Opportunities Does PGEN Have?
- Expansion of UltraCAR-T platform to new cancer indications.
- Development of novel immunotherapies using AdenoVerse.
- Commercialization of regenerative medicine products.
- Strategic partnerships and licensing agreements.
What Threats Does PGEN Face?
- Competition from established pharmaceutical companies.
- Unfavorable clinical trial results.
- Regulatory delays or rejections.
- Patent disputes and intellectual property challenges.
What Are PGEN's Competitive Advantages?
- Proprietary Technology Platforms: Precigen's UltraVector, AdenoVerse, and ActoBiotics platforms provide a competitive advantage through unique capabilities in gene and cell therapy development.
- Intellectual Property Portfolio: The company's extensive patent portfolio protects its innovative technologies and provides a barrier to entry for competitors.
- Strategic Collaborations: Partnerships with leading pharmaceutical and biotechnology companies enhance Precigen's reach and accelerate the development of its products.
- Expertise in Genetic Engineering: Precigen's team of scientists and engineers possesses deep expertise in genetic engineering and synthetic biology, enabling the company to develop novel therapeutic solutions.
What Does PGEN Do?
Precigen, Inc., founded in 1998 and formerly known as Intrexon Corporation until its rebranding in January 2020, is a biotechnology company headquartered in Germantown, Maryland. The company is dedicated to discovering and developing next-generation gene and cellular therapies. Precigen's portfolio includes disease-modifying therapeutics, genetically engineered swine for regenerative medicine applications, and reproductive and embryo transfer technologies. Its core offerings are built around several key technology platforms. The UltraVector platform incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs. Other platforms include mbIL15, Sleeping Beauty, AttSite recombinases, and AdenoVerse. These technologies are applied in the development of innovative therapies and solutions across various healthcare applications. Precigen also offers RheoSwitch, an inducible gene switch system, kill switches for cell therapies, tissue-specific promoters, UltraCAR-T platform for cancer treatment, AdenoVerse Immunotherapy, and ActoBiotics platform. The company collaborates with entities like Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., Intrexon Energy Partners, LLC, and Intrexon Energy Partners II, LLC, to expand its research and development efforts and commercial reach.
What Products and Services Does PGEN Offer?
- Discovers and develops gene and cellular therapies.
- Provides disease-modifying therapeutics.
- Develops genetically engineered swine for regenerative medicine.
- Offers reproductive and embryo transfer technologies.
- Provides the UltraVector platform for advanced DNA construction.
- Develops the AdenoVerse technology platform for gene delivery.
- Offers the RheoSwitch inducible gene switch system.
- Develops the UltraCAR-T platform for cancer treatment.
How Does PGEN Make Money?
- Develops and licenses gene and cell therapy technologies.
- Generates revenue through collaboration and license agreements.
- Conducts research and development to create innovative therapeutics.
- Commercializes its therapeutic products through partnerships or direct sales.
What Industry Does PGEN Operate In?
Precigen operates within the rapidly evolving biotechnology industry, specifically in the gene and cell therapy sector. This market is characterized by high growth potential, driven by advancements in genetic engineering and increasing demand for personalized medicine. The competitive landscape includes companies like TERN: Terns Pharmaceuticals, Inc. and DNTH: Dianthus Therapeutics, Inc., as well as larger pharmaceutical firms investing in gene and cell therapies. The industry is subject to stringent regulatory requirements and high research and development costs. Market trends include the development of novel delivery systems and the expansion of gene and cell therapies into new therapeutic areas.
Who Are PGEN's Key Customers?
- Pharmaceutical companies seeking gene and cell therapy technologies.
- Research institutions conducting studies in regenerative medicine.
- Hospitals and clinics offering advanced cancer treatments.
- Patients in need of innovative therapeutic solutions.
Precigen, Inc. (PGEN) Valuation Context
Valued at $1.69B, PGEN is classified as a small-cap stock. Relative to its peer group, PGEN's quantitative score of 14/100 is below the peer average of 71/100.
Key Financial Metrics
Its free cash flow yield is -7.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.82 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -12.1%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 4/9Financial Health
Precigen, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -18.95 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Precigen, Inc. revenue of about $124.3M for fiscal 2026, with EPS near $-0.03.
PGEN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests those in the know see long-term value, potentially signaling undervaluation.
- The community buzz seems optimistic about Precigen's pipeline, especially their gene and cell therapy programs.
- Market perception is shifting towards personalized medicine, a space where Precigen is actively innovating.
- Positive discussions highlight Precigen's strategic partnerships, which could unlock future growth opportunities.
Bear Case
- Despite insider buying, overall sentiment remains cautious due to past volatility.
- Community concerns linger regarding the timeline for commercializing their therapies and achieving profitability.
- Market perception is skeptical about the long-term viability of gene therapy companies without proven blockbuster drugs.
- Some bearish views focus on potential regulatory hurdles and the high costs associated with developing novel therapies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · February 2026
PGEN Latest News
-
Why Cisco Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
benzinga · May 14, 2026
-
Earnings Scheduled For May 13, 2026
benzinga · May 13, 2026
-
Three Growth Companies With Strong Insider Ownership To Consider
Simply Wall St. · May 12, 2026
-
Earnings Scheduled For November 13, 2025
benzinga · Nov 13, 2025
PGEN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PGEN.
Price Targets
Wall Street price target analysis for PGEN.
PGEN MoonshotScore
What does this score mean?
The MoonshotScore rates PGEN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Why Cisco Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
Earnings Scheduled For May 13, 2026
Three Growth Companies With Strong Insider Ownership To Consider
Earnings Scheduled For November 13, 2025
Leadership: Helen Sabzevari
CEO
Helen Sabzevari brings extensive experience in the biotechnology and pharmaceutical industries to her role as CEO of Precigen, Inc. Prior to joining Precigen, she held leadership positions at several prominent companies, including as Senior Vice President of Global Oncology at GlaxoSmithKline. She has a strong background in immunology and oncology, with a focus on developing innovative therapies for cancer and other diseases. Sabzevari holds a Ph.D. in Immunology from the University of California, Davis.
Track Record: Since becoming CEO, Helen Sabzevari has focused on streamlining Precigen's operations and advancing its key therapeutic programs. She has overseen the progress of the UltraCAR-T and AdenoVerse platforms through clinical trials and has forged strategic partnerships to expand the company's reach. Her leadership has been instrumental in shaping Precigen's strategic direction and positioning it for future growth.
PGEN Healthcare Stock FAQ
What does Precigen, Inc. do?
Precigen, Inc. is a biotechnology company focused on developing gene and cell therapies for various diseases. The company utilizes proprietary technology platforms such as UltraVector, AdenoVerse, and ActoBiotics to create innovative therapeutics. Precigen's business model involves developing and licensing these technologies, as well as conducting research and development to create new therapeutic products. The company generates revenue through collaboration agreements, licensing fees, and potential future sales of its therapeutic products. Precigen aims to address unmet medical needs by providing advanced solutions in gene and cell therapy.
What do analysts say about PGEN stock?
Analyst coverage of Precigen, Inc. (PGEN) is mixed, reflecting the inherent risks and potential rewards associated with biotechnology companies. Some analysts highlight the company's innovative technology platforms and diverse therapeutic pipeline as positive factors. However, concerns remain regarding the company's high operating expenses, negative profit margin, and dependence on clinical trial outcomes. Valuation metrics vary widely, with some analysts assigning higher price targets based on the potential of Precigen's lead therapeutic candidates. Investors should conduct their own due diligence and consider their risk tolerance before investing in PGEN.
What are the main risks for PGEN?
Precigen, Inc. faces several key risks inherent to the biotechnology industry. Clinical trial risk is significant, as unfavorable results for its key therapeutic programs could negatively impact the company's valuation. Regulatory risk is also a concern, as delays or rejections of new products by regulatory agencies could hinder commercialization efforts. Competition from established pharmaceutical companies with greater resources poses a threat. Financial risks include high operating expenses, a negative profit margin, and the need to secure additional funding to support ongoing research and development. Patent disputes and intellectual property challenges could also impact the company's competitive position.
What are the key factors to evaluate for PGEN?
Precigen, Inc. (PGEN) holds an AI score of 14/100 (low). Not financial advice.
How frequently does PGEN data refresh on this page?
PGEN prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven PGEN's recent stock price performance?
Precigen, Inc. (PGEN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative technology platforms (UltraVector, AdenoVerse). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PGEN overvalued or undervalued right now?
Valuing Precigen, Inc. (PGEN) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying PGEN?
Before investing in Precigen, Inc. (PGEN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Financial data is based on the most recent filings and may not be indicative of future performance.